Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention
Related Experiment Video
Updated: Jun 22, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dean J Kereiakes1, Paul A Gurbel
1Christ Hospital Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio 45219, USA. lindner@fuse.net
Insights
High pre-procedural platelet reactivity increases ischemic event risk after percutaneous coronary intervention. Achieving optimal platelet inhibition is key to improving patient outcomes and reducing adverse events.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Pre-procedural platelet reactivity is linked to adverse ischemic events post-percutaneous coronary intervention (PCI).
- Patients with high reactivity show varied responses to standard antiplatelet drugs, leading to higher residual platelet activity.
- Peri-procedural platelet inhibition correlates inversely with adverse clinical outcomes, especially myocardial infarction.
Purpose of the Study:
- To explore the relationship between pre-procedural platelet reactivity and outcomes following PCI.
- To investigate the impact of platelet inhibition levels on clinical events.
- To discuss the variability in antiplatelet response and future therapeutic directions.
Main Methods:
- Review of existing literature correlating pre-procedural platelet reactivity with PCI outcomes.
- Analysis of studies examining the relationship between platelet inhibition and adverse clinical events.
- Examination of data on interindividual variability in response to aspirin and clopidogrel.
Main Results:
- High pre-PCI platelet reactivity is associated with increased risk of ischemic events.
- Optimal post-treatment platelet reactivity (e.g., <40-50% aggregation) correlates with better long-term outcomes.
- Significant interindividual variability in response to aspirin and clopidogrel exists, with hyporesponsiveness linked to adverse outcomes.
Conclusions:
- Achieving adequate platelet inhibition is crucial for improving outcomes after PCI.
- Individual responses to antiplatelet agents vary, necessitating personalized approaches.
- Emerging anticoagulation and antiplatelet therapies may enhance peri-procedural pharmacotherapy safety and efficacy.
Abstract:
Pre-procedural platelet reactivity has been correlated with adverse ischemic events following percutaneous coronary intervention. Patients with high pre-percutaneous coronary intervention platelet reactivity demonstrate a differential response to standard doses of antiplatelet therapies and have higher residual post-treatment platelet reactivity. Peri-procedural platelet inhibition has been inversely correlated with the occurrence of adverse clinical outcomes, particularly myocardial infarction. Preliminary evidence supports the concept of a threshold for post-treatment platelet reactivity, and patients with less than 40% to 50% residual aggregation in response to 20-micromol/l adenosine diphosphate appear to have the best long-term clinical outcomes. Wide interindividual variability in response to either aspirin or clopidogrel has been demonstrated, and hyporesponsiveness to either agent has been associated with adverse clinical outcomes. Although the prevalence of either aspirin or clopidogrel resistance may be reduced by increasing the dose of medication, it cannot be eliminated, and interindividual variability in response persists. The advent of direct-acting antithrombin agents for peri-procedural anticoagulation coupled with novel antiplatelet therapies on the immediate horizon promise to enhance the safety and efficacy of peri-procedural adjunctive pharmacotherapy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:27Coronary Artery Disease V: Interprofessional Care